What do systematic reviews say?

Behavioural activation vs treatment

Behavioural activation showed no clear difference in treatment acceptabilityup to 6 months (5‐12 weeks) compared with treatment (moderate certainty).

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  RR 1.64 [0.81, 3.31]
  14 studies · 2518 participants
  Moderate

Behavioural activation vs third‐wave CBT

Behavioural activation showed no clear difference in treatment acceptability up to 6 months (4‐8 weeks) compared with third‐wave CBT (low certainty).

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  RR 0.84 [0.33, 2.1]
  3 studies · 147 participants
  Low

Behavioural activation vs any comparator

Behavioural activation showed no clear difference in treatment acceptability (short term: 2 months) compared with any comparator (low certainty).

• Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes only
  RR 1.81 [0.68, 4.82]
  1 study · 80 participants
  Low
• Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.25, 3.1]
  1 study · 101 participants
  Low

Hinokitiol gel vs Placebo gel

Hinokitiol gel showed no clear difference in VSC: methyl mercaptan compared with placebo gel; GRADE not reported.

• Interventions for managing halitosis 2019 · Cochrane All outcomes

  28 days
  MD -1.64 [-5.77, 2.49]
  1 study · 18 participants
  GRADE not reported

Chlorine dioxide mouthrinse (with tongue scraping) vs Chlorhexidine mouthwash (with tongue scraping)

Chlorine dioxide mouthrinse (with tongue scraping) showed no clear difference in VSC: methyl mercaptan compared with chlorhexidine mouthwash (with tongue scraping); GRADE not reported.

• Interventions for managing halitosis 2019 · Cochrane All outcomes

  1 week
  MD 7.63 [-1.7, 16.96]
  1 study · 22 participants
  GRADE not reported

Benzethonium chloride mouthwash vs Placebo mouthwash

Benzethonium chloride mouthwash showed no clear difference in VSC: methyl mercaptan compared with placebo mouthwash; GRADE not reported.

• Interventions for managing halitosis 2019 · Cochrane All outcomes

  9 days
  MD 7.2 [-24.92, 39.32]
  1 study · 20 participants
  GRADE not reported

Antidepressants plus benzodiazepines vs antidepressants alone

Antidepressants plus benzodiazepines showed no clear difference in acceptability of treatment (dropout for any reason) compared with antidepressants alone (moderate certainty).

• Antidepressants plus benzodiazepines for adults with major depression 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.54, 1.07]
  10 studies · 731 participants
  Moderate

Adverse event outcomes for physical activity interventions vs control

• Interventions for preventing obesity in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 546 participants
  Moderate

Vaginal misoprostol vs surgical evacuation of uterus

Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).

• Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
  RR 0.67 [0.4, 1.11]
  1 study · 45 participants
  Low

Vaginal misoprostol vs placebo

Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).

• Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
  RR 1.17 [0.83, 1.64]
  1 study · 32 participants
  Low

Lithium vs valproate

Lithium showed no clear difference in acceptability: total withdrawals compared with valproate (high certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.2 [0.86, 1.69]
  5 studies · 629 participants
  High

Lithium vs lamotrigine

It is very uncertain whether lithium changes acceptability: total withdrawals compared with lamotrigine (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.8 [0.5, 1.29]
  3 studies · 303 participants
  Very low

Lithium vs carbamazepine

Lithium showed no clear difference in acceptability: total withdrawals compared with carbamazepine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.2 [0.02, 1.94]
  1 study · 34 participants
  Low

Lithium vs QUETIAPINE

It is very uncertain whether lithium changes acceptability: total withdrawals compared with quetiapine (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.38 [0.83, 2.28]
  2 studies · 359 participants
  Very low

Lithium vs OLANZAPINE

Lithium may leads to higher acceptability: total withdrawals compared with olanzapine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 2.6 [1.13, 5.99]
  3 studies · 210 participants
  Low

Lithium vs placebo

Lithium showed no clear difference in acceptability: total withdrawals compared with placebo (moderate certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.76 [0.46, 1.25]
  7 studies · 1353 participants
  Moderate

Lithium vs chlorpromazine

Lithium showed no clear difference in acceptability: total withdrawals compared with chlorpromazine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.75 [0.92, 3.31]
  2 studies · 262 participants
  Low

Lithium vs haloperidol

It is very uncertain whether lithium changes acceptability: total withdrawals compared with haloperidol (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.29 [0.03, 3.12]
  1 study · 30 participants
  Very low

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

It is very uncertain whether lithium changes acceptability: total withdrawals compared with zuclopenthixol (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.78 [0.17, 3.49]
  1 study · 28 participants
  Very low

Lithium vs RISPERIDONE

Lithium probably leads to higher acceptability: total withdrawals compared with risperidone (moderate certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.85 [1.02, 3.34]
  3 studies · 255 participants
  Moderate